We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
-4.95%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$882M
AUM Growth
+$331M
(+60%)
Cap. Flow
+$358M
Cap. Flow
% of AUM
40.55%
Top 10 Holdings %
Top 10 Hldgs %
95.59%
Holding
16
New
2
Increased
7
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$25.3M |
| 2 |
Arvinas
ARVN
|
+$17M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$13M |
| 4 |
Arrowhead Research
ARWR
|
+$11.9M |
| 5 |
4D Molecular Therapeutics
FDMT
|
+$10M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$49.5M |
| 2 |
uniQure
QURE
|
+$18.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
| $475M | 53.87% |
+1,000,000
| New | +$459M |
|
2
Spero Therapeutics
SPRO
$73M
| $79.5M | 9.01% |
4,964,181
+400,493
| +9% | +$6.36M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $69.1M | 7.84% |
645,539
+123,866
| +24% | +$13M |
|
|
4
Arrowhead Research
ARWR
$12.4B
| $46.4M | 5.27% |
700,426
+172,500
| +33% | +$11.9M |
|
|
5
Arvinas
ARVN
$572M
| $46.3M | 5.25% |
563,451
+208,740
| +59% | +$17M |
|
6
Regenxbio
RGNX
$708M
| $33.1M | 3.76% |
1,013,596
+174,457
| +21% | +$5.94M |
|
|
7
4D Molecular Therapeutics
FDMT
$562M
| $33.1M | 3.76% |
1,509,944
+410,000
| +37% | +$10M |
|
|
MRUS
8
DELISTED
Merus
MRUS
| $28.5M | 3.23% |
+896,502
| New | +$25.3M |
|
|
AMYT
9
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $17.7M | 2.01% |
1,640,000
+250,000
| +18% | +$2.7M |
|
|
10
uniQure
QURE
$3.22B
| $14M | 1.59% |
676,206
-643,307
| -49% | -$18.4M |
|
11
Dianthus Therapeutics
DNTH
$6.09B
| $14M | 1.59% |
197,193
| – | – |
|
|
PVLA
12
Palvella Therapeutics
PVLA
$2.27B
| $12.1M | 1.37% |
39,957
| – | – |
|
13
argenx
ARGX
$54.1B
| $7.77M | 0.88% |
22,200
| – | – |
|
14
Genmab
GMAB
$19.5B
| $5.04M | 0.57% |
127,500
| – | – |
|
15
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| – | – |
-1,000,000
| Closed | -$126M |
|
|
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-2,456,595
| Closed | -$49.5M |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Aquilo Capital Management held 16 positions worth $882M, up 60% from $551M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Aquilo Capital Management deployed $358M of net new capital in Q4 2021, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was Merus: 896,502 shares worth $28.5M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 68% a quarter earlier.
On the sell side, the largest reduction was uniQure, an estimated $18.4M trimmed.
- Aquilo Capital Management's largest Q4 2021 buy was Merus: 896,502 shares worth $28.5M.
- Aquilo Capital Management added most to Arvinas in Q4 2021, an estimated $17M increase.
- Aquilo Capital Management's biggest Q4 2021 reduction was uniQure, cutting an estimated $18.4M.
- Aquilo Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $49.5M.
- Aquilo Capital Management's ten largest holdings make up 96% of its $882M portfolio in Q4 2021.
- Aquilo Capital Management opened 2 new positions and closed 2 in Q4 2021.
- Aquilo Capital Management's portfolio value rose 60% quarter-over-quarter to $882M.
Based on Aquilo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.